156 related articles for article (PubMed ID: 21707500)
1. Therapeutic strategies to target multiple kinases in glioblastoma.
Sathornsumetee S
Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
[TBL] [Abstract][Full Text] [Related]
2. Targeting multiple kinases in glioblastoma multiforme.
Sathornsumetee S; Reardon DA
Expert Opin Investig Drugs; 2009 Mar; 18(3):277-92. PubMed ID: 19243279
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
[TBL] [Abstract][Full Text] [Related]
4. Atypical PKCĪ¹ as target for glioblastoma therapy.
Lorimer IA
Curr Cancer Drug Targets; 2015; 15(2):136-44. PubMed ID: 25643257
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
[TBL] [Abstract][Full Text] [Related]
6. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
Zhou A
Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
[TBL] [Abstract][Full Text] [Related]
7. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
8. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
9. PKC eta as a therapeutic target in glioblastoma multiforme.
Martin PM; Hussaini IM
Expert Opin Ther Targets; 2005 Apr; 9(2):299-313. PubMed ID: 15934917
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib in glioblastoma: lost in translation?
Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
[TBL] [Abstract][Full Text] [Related]
12. Targeting the AKT pathway in glioblastoma.
McDowell KA; Riggins GJ; Gallia GL
Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
[TBL] [Abstract][Full Text] [Related]
13. Recent medical management of glioblastoma.
Johnson DR; Chang SM
Adv Exp Med Biol; 2012; 746():26-40. PubMed ID: 22639157
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
16. Designer therapies for glioblastoma multiforme.
Sathornsumetee S; Rich JN
Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
[TBL] [Abstract][Full Text] [Related]
17. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
18. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
19. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
[TBL] [Abstract][Full Text] [Related]
20. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]